Loading publications…
The last 5 uploaded publications
Early changes in PSA and association with outcomes in mCRPC patients.
Pasquale Rescigno, David Dolling, Mattia Rediti, Vincenza Conteduca, Michael Ong, Haoran Li, Aurelius Omlin, Sabine Schmid, Orazio Caffo, Andrea Zivi, Carmel Pezaro, Courtney Morley, Nuria Romero-Laorden, M.I. Sáez, Niven Mehra, Spyridon Sideris, Shahneen Sandhu, Cora N. Sternberg, Ugo De Giorgi, Johann S. de Bono (2018). Early changes in PSA and association with outcomes in mCRPC patients.. , 36(15_suppl), DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.5063.
Article62 days agoImproved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms
Aurelius Omlin, Carmel Pezaro, Deborah Mukherji, Amy Mulick, Shahneen Sandhu, Diletta Bianchini, David Olmos, Roberta Ferraldeschi, Gal Maier, Emilda Thompson, Chris Parker, Gerhardt Attard, Johann S. de Bono (2013). Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms. , 64(2), DOI: https://doi.org/10.1016/j.eururo.2012.12.029.
Article62 days agoFinal results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving <i>BRCA1/2</i> mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC).
Caroline O. Michie, Shahneen Sandhu, William R. Schelman, L. Rhoda Molife, George Wilding, Aurelius Omlin, Vikram Kansra, David G. Brooks, Robert E. Martell, Stanley B. Kaye, Johann S. de Bono, Robert M. Wenham (2013). Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving <i>BRCA1/2</i> mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC).. , 31(15_suppl), DOI: https://doi.org/10.1200/jco.2013.31.15_suppl.2513.
Article62 days agoPoly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
Shahneen Sandhu, Aurelius Omlin, Lucy Hylands, Susana Miranda, Louise J. Barber, Ruth Riisnaes, Alison Reid, Gerhardt Attard, L. Chen, Iwanka Kozarewa, Heidi Gevensleben, James Campbell, Kerry Fenwick, Ioannis Assiotis, David Olmos, Timothy A. Yap, Peter C.C. Fong, Nina Tunariu, Dow‐Mu Koh, L. Rhoda Molife, S.B. Kaye, Christopher J. Lord, Alan Ashworth, Johann S. de Bono (2013). Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. , 24(5), DOI: https://doi.org/10.1093/annonc/mdt074.
Letter62 days agoReply: ‘Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer’
Aurelius Omlin, Carmel Pezaro, S. Zaidi, David Lorente, Deborah Mukherji, Diletta Bianchini, Roberta Ferraldeschi, Shahneen Sandhu, David P. Dearnaley, Chris Parker, Nicholas van As, Johann S. de Bono, Gerhardt Attard (2013). Reply: ‘Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer’. , 110(1), DOI: https://doi.org/10.1038/bjc.2013.737.
Letter62 days ago